The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Haloperidol versus placebo for schizophrenia
|
---|---|
Published in |
Cochrane database of systematic reviews, November 2013
|
DOI | 10.1002/14651858.cd003082.pub3 |
Pubmed ID | |
Authors |
Clive E Adams, Hanna Bergman, Claire B Irving, Stephen Lawrie |
Abstract |
Haloperidol was developed in the late 1950s for use in the field of anaesthesia. Research subsequently demonstrated effects on hallucinations, delusions, aggressiveness, impulsiveness and states of excitement and led to the introduction of haloperidol as an antipsychotic. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 50% |
Spain | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 292 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | <1% |
United Kingdom | 1 | <1% |
Portugal | 1 | <1% |
Unknown | 288 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 49 | 17% |
Student > Bachelor | 34 | 12% |
Researcher | 31 | 11% |
Student > Ph. D. Student | 30 | 10% |
Other | 17 | 6% |
Other | 56 | 19% |
Unknown | 75 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 90 | 31% |
Psychology | 40 | 14% |
Nursing and Health Professions | 21 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 12 | 4% |
Neuroscience | 8 | 3% |
Other | 37 | 13% |
Unknown | 84 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2020.
All research outputs
#1,769,014
of 25,806,763 outputs
Outputs from Cochrane database of systematic reviews
#3,761
of 13,140 outputs
Outputs of similar age
#15,679
of 224,621 outputs
Outputs of similar age from Cochrane database of systematic reviews
#82
of 249 outputs
Altmetric has tracked 25,806,763 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,140 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.9. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 224,621 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 249 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.